SciSparc (NASDAQ:SPRC) Upgraded at Wall Street Zen

SciSparc (NASDAQ:SPRC) was upgraded by Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a report on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

SciSparc Stock Down 6.7%

SPRC stock opened at $5.00 on Friday. The company has a 50-day simple moving average of $6.51 and a 200 day simple moving average of $6.55. SciSparc has a fifty-two week low of $2.98 and a fifty-two week high of $80.10.

SciSparc (NASDAQ:SPRC) last released its earnings results on Wednesday, April 29th. The company reported ($31.60) EPS for the quarter. The business had revenue of $0.20 million for the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.